BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Mederi Therapeutics Inc. Release: Stretta® Therapy for GERD Receives Strongest Recommendation in SAGES New Clinical Guideline


2/11/2013 9:33:31 AM

GREENWICH, Conn., Feb. 11, 2013 /PRNewswire/ -- Mederi Therapeutics Inc. today announced that the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) has issued new Clinical Guidelines that strongly recommend Stretta therapy for the treatment of Gastroesophageal Reflux Disease (GERD). The SAGES Clinical Spotlight Review (CSR) process entails an in-depth analysis of the available peer-reviewed clinical evidence, focusing on randomized, controlled studies, as well as long-term follow up showing durability of treatment effect. The clinical evidence in support of Stretta was assigned a grade of ++++, achieving the highest possible recommendation. "The new Clinical Spotlight Review for endoluminal GERD therapies strongly supports the safety and effectiveness of Stretta as illustrated through the depth of clinical data. The body of data shows unequivocally that Stretta is a valuable minimally invasive tool for the treatment of GERD," stated Dr. Scott Melvin, current President of SAGES.

(Photo: http://photos.prnewswire.com/prnh/20130211/NY56794 )

Stretta is a minimally-invasive endoscopic treatment that delivers radiofrequency (RF) energy to remodel the lower esophageal sphincter muscle, offering significant relief of GERD symptoms. In reference to Stretta, the guidelines stated, "More than 30 peer reviewed studies, including 4 adequately powered randomized, controlled studies, a comprehensive meta-analysis and multiple prospective clinical trials have documented the safety and efficacy of the Stretta procedure. Durable treatment outcomes to at least 48 months also have been demonstrated in multiple studies, with significant reduction or elimination of medications used to treat the symptoms of GERD, as well as improvement in GERD QOL and symptom scores." This guideline was developed under the auspices of SAGES and its various committees, and approved by the SAGES Board of Governors. "We are encouraged that insurance companies will take note of this guideline and update their coverage policies to make Stretta available to the many sufferers of GERD," stated Bill Reynolds, Mederi's VP of Reimbursement & Payer Strategy.

"It is extremely gratifying to have a scientific analysis of the overwhelming body of clinical evidence supporting Stretta issued by an esteemed organization such as SAGES. The grade of 'Strong' indicates that no further studies are necessary to validate Stretta as a safe and effective treatment for GERD," stated Will Rutan, CEO of Mederi Therapeutics.

To access the complete SAGES Clinical Spotlight Review go to http://www.sages.org/publication/id/CSR1/.

For more information go to stretta-therapy.com.

ABOUT STRETTA®
Stretta Therapy is a minimally invasive treatment for GERD that is an effective option for patients who do not respond well to medications. Stretta involves delivery of RF to the LES and gastric cardia. Clinical studies show Stretta to be a safe, effective and durable therapeutic option. Stretta therapy does not preclude further steps with more invasive procedures if indicated.

ABOUT MEDERI®
Mederi Therapeutics manufactures and markets innovative medical devices that deliver RF energy to treat disease states affecting the digestive system. All Mederi therapies are outpatient, minimally invasive and promote rapid recovery. Mederi Therapeutics is located in Greenwich, Connecticut.

Contact: Sheila Doyle, 203-930-9980, sdoyle@mederitherapeutics.com

SOURCE Mederi Therapeutics Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES